EMA Authorised: Puregon (follitropin beta) — Organon N.V.

View source ↗

Summary

The EMA authorised Puregon (follitropin beta) for infertility and hypogonadism, with Organon N.V. listed as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism
• Infertility

Drugs mentioned

• Puregon (follitropin beta)

Snippet

Status: Authorised. Therapeutic area: Infertility;Hypogonadism. MAH: Organon N.V.. Decision date: 18/12/2025